Net Cash Provided by (Used in) Financing Activities in USD of Dermata Therapeutics, Inc. from 2020 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Dermata Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2020 to Q1 2025.
  • Dermata Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $8,491,764.
  • Dermata Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $6,886,383, a 9.5% decline from 2023.
  • Dermata Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $7,605,772, a 78% increase from 2022.
  • Dermata Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $4,276,652, a 73% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Dermata Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $8,491,764 +$8,491,764 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q1 2024 $0 -$4,175,098 -100% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q1 2023 $4,175,098 +$4,175,098 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q1 2022 $0 -$1,576,235 -100% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $1,576,235 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1

Dermata Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,886,383 -$719,389 -9.5% 01 Jan 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
2023 $7,605,772 +$3,329,120 +78% 01 Jan 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
2022 $4,276,652 -$11,685,146 -73% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $15,961,798 +$13,394,659 +522% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2023 2022 FY
2020 $2,567,139 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.